EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.87

Change

+0.65 (+6.36)%

Market Cap

N/A

Volume

1.50M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-22 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.90 (-0.54%)

USD 76.41B
HLN Haleon plc

-0.02 (-0.22%)

USD 42.79B
TAK Takeda Pharmaceutical Co Ltd A..

-0.21 (-1.60%)

USD 41.33B
RDY Dr. Reddy’s Laboratories Ltd..

+0.29 (+1.96%)

USD 12.60B
ELAN Elanco Animal Health

+0.06 (+0.50%)

USD 5.65B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.04 (-0.47%)

USD 3.68B
BHC Bausch Health Companies Inc

+0.25 (+3.35%)

USD 2.91B
CPHI China Pharma Holdings Inc

-0.01 (-2.82%)

USD 3.69M
YCBD cbdMD Inc

-0.02 (-4.26%)

USD 1.96M
EVT Eaton Vance Tax Advantaged Div..

-0.03 (-0.12%)

N/A

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 19.72 % 0.00 %

N/A

USD 0.04B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 19.25 % 0.00 %

+0.05 (+-0.50%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 18.99 % 0.00 %

-0.06 (-0.50%)

USD 0.09B
BNKE:LSE Lyxor EURO STOXX Banks UC.. 3.04 % 0.00 %

-1.40 (-0.50%)

USD 0.30M
C005:XETRA Amundi Index Solutions - .. 2.32 % 0.00 %

+0.14 (+-0.50%)

USD 0.13B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 2.22 % 0.00 %

+0.27 (+-0.50%)

USD 0.13B
BINV 2023 ETF Series Trust - B.. 2.15 % 0.00 %

-0.16 (-0.50%)

USD 0.14B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.93 % 0.00 %

+0.41 (+-0.50%)

USD 0.14B
FTGE:XETRA First Trust Eurozone Alph.. 1.34 % 0.00 %

-0.09 (-0.50%)

USD 0.08B
FEUZ:LSE First Trust Eurozone Alph.. 1.32 % 0.00 %

-7.00 (-0.50%)

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 1.32 % 0.00 %

-6.25 (-0.50%)

USD 0.01B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+2.10 (+-0.50%)

N/A
LDEU:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+0.01 (+-0.50%)

USD 0.04B
EL43:XETRA Deka MSCI Europe MC UCITS.. 1.18 % 0.00 %

+0.03 (+-0.50%)

USD 0.02B
EUMD:LSE iShares MSCI Europe Mid C.. 1.18 % 0.00 %

+0.04 (+-0.50%)

USD 0.28B
FEP First Trust Europe AlphaD.. 1.02 % 0.80 %

-0.23 (-0.50%)

USD 0.19B
FDT First Trust Developed Mar.. 0.66 % 0.80 %

+0.05 (+-0.50%)

USD 0.39B
PRFZ Invesco FTSE RAFI US 1500.. 0.35 % 0.39 %

-0.25 (-0.50%)

USD 2.60B
IS3T:XETRA iShares MSCI World Size F.. 0.15 % 0.00 %

-0.06 (-0.50%)

USD 0.24B
FEUZ First Trust Eurozone Alph.. 0.00 % 0.80 %

-0.27 (-0.50%)

USD 0.02B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.15 (+-0.50%)

N/A
FTEU:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

-0.07 (-0.50%)

USD 0.06B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.70% 93% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.70% 93% A 95% A
Trailing 12 Months  
Capital Gain 478.19% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 478.19% 100% F 100% F
Trailing 5 Years  
Capital Gain -80.60% 23% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.60% 23% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -16.79% 7% C- 3% F
Dividend Return -16.79% 7% C- 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 105.60% 21% F 8% B-
Risk Adjusted Return -15.90% 21% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector